Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Dec 12;10(12):510.
doi: 10.3390/cancers10120510.

Management of Typical and Atypical Pulmonary Carcinoids Based on Different Established Guidelines

Rohit Gosain  1 , Sarbajit Mukherjee  2   3 , Sai S Yendamuri  4 , Renuka Iyer  5
Affiliations
Review

Management of Typical and Atypical Pulmonary Carcinoids Based on Different Established Guidelines

Rohit Gosain et al. Cancers (Basel). .

Abstract

Neuroendocrine tumors (NETs) are a group of malignancies that originated from neuroendocrine cells, with the most common sites being lungs and the gastrointestinal tract. Lung NETs comprise 25% of all lung malignancies. Small cell lung cancer is the most common form of lung NETs, and other rare forms include well-differentiated typical carcinoids (TCs) and poorly differentiated atypical carcinoids (ACs). Given the paucity of randomized studies, rational treatment is challenging. Therefore, it is recommended that these decisions be made using a multidisciplinary collaborative approach. Surgery remains the mainstay of treatment, when feasible. Following surgery, various guidelines offer different recommendations in the adjuvant setting. In this paper, we describe the adjuvant management of lung NETs, as recommended by different guidelines, and highlight their differences. In addition to that, we also discuss the management of metastatic lung NETS, including the use of peptide receptor radionucleotide therapy.

Keywords: adjuvant therapy; atypical carcinoid; guideline; lung NET; pulmonary neuroendocrine tumors; typical carcinoid.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

References

    1. Yao J.C., Hassan M., Phan A., Dagohoy C., Leary C., Mares J.E., Abdalla E.K., Fleming J.B., Vauthey J.N., Rashid A., et al. One hundred years after “carcinoid”: Epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J. Clin. Oncol. 2008;26:3063–3072. doi: 10.1200/JCO.2007.15.4377. - DOI - PubMed
    1. Travis W.D. Advances in neuroendocrine lung tumors. Ann. Oncol. 2010;21:vii65–vii71. doi: 10.1093/annonc/mdq380. - DOI - PubMed
    1. Travis W.D., Brambilla E., Muller-Hermelink H.K., Harris C.C. Pathology and genetics of tumours of the lung. Bull. World Health Organ. 2004;50:9–19.
    1. Ferguson M.K., Landreneau R.J., Hazelrigg S.R., Altorki N.K., Naunheim K.S., Zwischenberger J.B., Kent M., Yim A.P.C. Long-term outcome after resection for bronchial carcinoid tumors. Eur. J. Cardio-Thorac. Surg. 2000;18:156–161. doi: 10.1016/S1010-7940(00)00493-0. - DOI - PubMed
    1. Gustafsson B.I., Kidd M., Chan A., Malfertheiner M V., Modlin I.M. Bronchopulmonary neuroendocrine tumors. Cancer. 2008;113:5–21. doi: 10.1002/cncr.23542. - DOI - PubMed

LinkOut - more resources